aTyr Pharma reports Q1 EPS (23c), consensus (24c)

Reports Q1 revenue $235K, consensus $20K…Cash, cash equivalents, restricted cash and investments as of March 31 , were $87.7M. Based on the Company’s current operational plans and existing cash, the company maintains its prior guidance and believes its cash runway will be sufficient to fund the Company’s operations through the filing of a Biologics License Application c for efzofitimod in pulmonary sarcoidosis.Collaboration and license revenue related to the Kyorin Agreement was $0.2 million for the first quarter of 2024, which consisted of drug product material sold to Kyorin for the Japan portion of the EFZO-FIT study….”During the first quarter of 2024 we continued to execute on our two clinical studies for our lead therapeutic candidate, efzofitimod, in interstitial lung disease ,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “We are pleased with the study conduct and quality to date for our global pivotal Phase 3 EFZO-FIT(TM) study in patients with pulmonary sarcoidosis, a major form of ILD with high unmet medical need, and we look forward to completing enrollment in this study, which is anticipated this quarter.”